Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DuPont Innohep

Executive Summary

FDA objects to July 18 tinzaparin press release for implying that "Innohep is indicated for use in all [deep vein thrombosis] patients, that it is approved for monotherapy and that it is the only low molecular weight heparin that is administered once-a-day." Innohep was approved by FDA July 14 for acute DVT with or without pulmonary embolism in combination with warfarin (1"The Pink Sheet" July 24, p. 13)

You may also be interested in...

DuPont's Innohep Anticoagulant Approved With Once-Daily Dosing Regimen

DuPont's low molecular weight heparin Innohep will enter the market as the only treatment with once-daily dosing for all patients with deep vein thrombosis. Other LMWHs have a mix of recommended dosages, which may include once-daily administration.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts